At a glance
- Originator Wakunaga Pharmaceutical
- Class Antibacterials; Quinolones
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 17 Oct 2007 Discontinued - Preclinical for Bacterial infections in Japan (unspecified route)
- 15 Oct 2002 This compound is still in active development
- 05 Jan 1998 Preclinical development for Bacterial infections in Japan (Unknown route)